These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7798300)

  • 1. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients.
    Wiltschke C; Kindas-Muegge I; Steininger A; Reiner A; Reiner G; Preis PN
    J Cancer Res Clin Oncol; 1994; 120(12):737-42. PubMed ID: 7798300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.
    Albanell J; Bellmunt J; Molina R; García M; Caragol I; Bermejo B; Ribas A; Carulla J; Gallego OS; Español T; Solé Calvo LA
    Anticancer Res; 1996; 16(2):1027-32. PubMed ID: 8687094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profile.
    Sidoni A; Cavaliere A; Bellezza G; Del Sordo R; Angiero F; Gori S; Rulli A; Bucciarelli E
    Tumori; 2006; 92(5):412-5. PubMed ID: 17168434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
    Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu oncogene expression in advanced breast cancer.
    Krogerus LA; Leivonen M
    Cancer Detect Prev; 2001; 25(1):1-7. PubMed ID: 11270416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
    Marks JR; Humphrey PA; Wu K; Berry D; Bandarenko N; Kerns BJ; Iglehart JD
    Ann Surg; 1994 Apr; 219(4):332-41. PubMed ID: 7909221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
    Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
    Ismail MF; Aly MS; Khaled HM; Mohamed HM
    Ger Med Sci; 2009 May; 7():Doc03. PubMed ID: 19675743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
    J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
    Isola J; Visakorpi T; Holli K; Kallioniemi OP
    J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DCC protein expression in breast carcinoma.
    Hsu YH; Shaw CK
    Kaohsiung J Med Sci; 2000 May; 16(5):233-40. PubMed ID: 10969518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu oncogene protein and prognosis in breast cancer.
    Tandon AK; Clark GM; Chamness GC; Ullrich A; McGuire WL
    J Clin Oncol; 1989 Aug; 7(8):1120-8. PubMed ID: 2569032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 positive and p53 negative breast cancers are associated with poor prognosis.
    Al-azawi D; Leong S; Wong L; Kay E; Hill AD; Young L
    Cancer Invest; 2011 Jun; 29(5):365-9. PubMed ID: 21599513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome.
    Amir G; Issakov J; Meller I; Sucher E; Peyser A; Cohen IJ; Yaniv I; Ben Arush MW; Tavori U; Kollender Y; Ron N; Peylan-Ramu N
    Hum Pathol; 2002 Feb; 33(2):170-4. PubMed ID: 11957141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.